Regulatory Considerations for the Development of Oligonucleotide Therapeutics

Handbook of Analysis of Oligonucleotides and Related Products

Volumn , Issue , 2011, Pages 465-486

  Srivatsa, G Susan ^a  

^a ElixinPharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82255194605     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b10714-24     Document Type: Chapter

References (62)

1. Food and Drug Administration (FDA) 1995 Guidance for industry: Content and format of investiga-tional new drug applications (INDs) for phase I studies of drugs, including well-characterized, therapeutic, biotechnology-derived products
2. Kambhampati, R., Y-Y. Chiu, C.W. Chen, et al. 1993. Regulatory concerns for the chemistry, manufac-turing and controls of oligonucleotide therapeutics for use in clinical studies Antisense Research and Development 3: 405-410
3. Kambhampati, R 2007 Points to consider for the submission of chemistry, manufacturing and controls (CMC) information in oligonucleotide-based therapeutic drug applications Center for Drug Evaluation Research, Office of New Drug Quality Assessment, US Food and Drug Administration, DIA Industry and Health Authority Conference on Oligonucleotide Therapeutics
4. International Conference on Harmonization (ICH) Q3A 2008 Impurities in new drug substances
5. ICH Q6A 1999. Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances
6. Sober, H. A., ed. 1969. Handbook of Biochemistry Selected Data for Molecular Biology. Cleveland, OH: Chemical Rubber Company
7. Schuette, J., U. Pieles, S. D. Maleknia, et al. 1995. Sequencing analysis of phosphorothioate oligo-nucleotides via matrix assisted laser desorption ionization time-of-flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 13: 1195-1203
8. Maxam, A M, and W Gilbert 1977 A new method for sequencing DNA. Proceedings of the National Academy of Sciences of the United States of America 74(2): 560-564
9. Little, D P, et al 1994 Rapid sequencing of oligonucleotides by high-resolution mass spectrometry. Journal of the American Chemical Society, 116(11): 4893-4897.
10. Bahr, U, H Aygun, and M Karas 2009 Sequencing of single and double stranded RNA oligonucle-otides by acid hydrolysis and MALDI mass spectrometry Analytical Chemistry 81(8): 3173-3179
11. Schuette, J., G. S. Srivatsa, and D. L. Cole. 1994. Development and validation of a method for routine base composition analysis of phosphorothioate oligonucleotides Journal of Pharmaceutical and Biomedical Analysis 12: 1345-1353
12. Emsley, J, and D Hall 1976 31P n m r and vibrational spectra of phosphorous compounds In The Chemistry of Phosphorus, 78-109. New York: Harper and Row.
13. Tsuboi, M, and Y Kyogoku 1973 Chapter 6 In Synthetic Procedures in Nucleic Acid Chemistry: Physical and Physicochemical Aids in Characterization and Determination of Structure, ed W W Zorbach, Vol. 2, 215-265. New York: John Wiley.
14. Wuthrich, K. 1986. NMR of Proteins and Nucleic Acids, 1-224. New York: John Wiley.
15. Stone, M. P., S. A. Winkle, G. D. McFarland, et al. 1985. 13C-NMR of ribosyl A-A-A, A-A-G, and A-U-G: synthesis and assignment Biophysical Chemistry 23: 129-138
16. Pretsch, E., P. Buhlmann, and C. Affolter. 2000. Structure Determination of Organic Compounds: Tables of Spectral Data. New York: Springer-Verlag.
17. Frier, S. 1993. Hybridization and antisense drugs. In Antisense Research and Applications, eds. S. Crooke and B. Lebleu, 67-82. Boca Raton, FL: CRC Press.
18. Srivatsa, G. S., P. Klopchin, M. Batt, et al. 1997. Selectivity of anion exchange HPLC and capillary gel electrophoresis for the analysis of phosphorothioate oligonucleotides. Journal of Pharmaceutical and Biomedical Analysis 16: 619-630.
19. Blackburn, M., and M. Gait. 1996. Chapter 10. In Nucleic Acids in Chemistry and Biology. New York: Oxford University Press.
20. Furtig, B., C. Richter, J. Wohnert, et al. 2003. NMR spectroscopy of RNA. Chembiochemistry 4(10): 936-962
21. Sanger, W. 1985. Chapter 5. In Principles ofNucleic Acid Structure. New York: Springer-Verlag.
22. Chen, D., and G. S. Srivatsa. 1999. n-1 deletion sequence analysis of oligonucleotides by hybridization to immobilized specific probes. Nucleic Acid Research 27(2): 389-395.
23. Temsamani, J., M. Kubert, and S. Agrawal. 1995. Sequence identity of the n-1 product of a synthetic oligonucleotide Nucleic Acids Research 23(11): 1841-1844
24. Fearon, K. L., J. T. Stults, B. J. Bergot, L. M. Christensen, and A. M. Raible. 1995. Investigation of the ʼn-1' impurity in phosphorothioate oligodeoxynucleotides synthesized by the solid-phase ß-cyanoethyl phosphoramidite method using stepwise sulfurization Nucleic Acids Research 23: 2754-2761
25. Krotz, A. H., P. G. Klopchin, K. L. Walker, G. S. Srivasta, D. L. Cole, and V. T. Ravikumar. 1997. On the formation of longmers in phosphorothioate oligodeoxyribonucleotide synthesis. Tetrahedron Letters 38: 3875-3878
26. Kurata, C., K. Bradley, H. Gaus, N. Luu, I. Cedillo, V. T. Ravikumar, K. Van Sooy, J. V. McArdle, and D. C. Capaldi. 2006. Characterization of high molecular weight impurities in synthetic phosphorothioate oligonucleotides. Bioorganic and Medicinal Chemistry Letters 16: 607-614.
27. Chen, D, P Klopchin, J Parsons, and G S Srivatsa 1997 Determination of sodium acetate in antisense oligonucleotides by capillary zone electrophoresis. Journal of Liquid Chromatography and Related Technologies 20(8): 1185-1195.
28. ICH Q7A. 2001. Good manufacturing practice guidance for active pharmaceutical ingredients.
29. Ravikumar, V. T., K. R. Kumar, P. Olsen, et al. 2008. UnyLinker: An efficient and scaleable synthesis of oligonucleotides utilizing a universal linker molecule: A novel approach to enhance the purity of drugs Organic Process Research and Development 12(3): 399-110.
30. Wyrzykiewicz, T A, and D L Cole 1995 Stereo-reproducibility of the phosphoramidite method in the synthesis of phosphorothioate oligonucleotides Bioorganic Chemistry 23: 33-41
31. Ravikumar, V., and D. L. Cole. 2002. Development of 2'-Methoxyethyl phosphorothioate oligonucleotide as antisense drugs under stereochemical control Organic Process Research and Development 6: 798-806
32. FDA 1998 Guidance for industry: Process validation: General principles and practices
33. ICH Q9 2001 Quality risk management
34. Srivatsa, G. S., A. Scozzari, and D. L. Cole. 2000. Special issues for synthetic antisense oligonucleotides. In Biopharmaceutical Process Validation, eds. G. Sofer and D. Zabriskie, 309-327, New York: Marcel Dekker, Inc
35. ICH Q4B 2008 Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions Annexes 1-10
36. Jiang, Z. -Y., J. V. Hunt, and S. P. Wolff. 1992. A simple Fe++-oxidation method for detection of lipid peroxide in low density lipoprotein and liposomes Analytical Biochemistry 202: 384-389
37. Kumar, V., and V. Kalonia. 2003. Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations AAPS PharmSciTech 7(3): Article 62
38. Krotz, A, R Mehta, and G Hardee 2005 Peroxide mediated desulfurization of phosphorothioates and its prevention Journal of Pharmaceutical Sciences 94(2): 341-352
39. ICH Q3B (R2) 2006 Impurities in new drug products
40. Srivatsa, G. S., M. Batt, J. S. Schuette, et al. 1994. Assay of phosphorothioate oligonucleotides in pharmaceuti-cal formulations by capillary gel electrophoresis (QCGE) Journal of Chromatography A 680: 469-477
41. FDA 2009 Guidance for industry: Residual solvents in drug products marketed in the United States
42. ICH Q3C 1997 Impurities: Residual solvents
43. USP 2006 General chapter on inorganic impurities: Heavy metals stimuli article
44. European Agency for the Evaluation of Medicinal Products (EMEA) 2002 Note for guidance on specification limits for residues of metal catalysts.
45. FDA 1987 Guideline on the validation of the LAL test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices
46. USP 34. 2011. General chapter on methods validation.
47. ICH Q2A 1995 Text on validation of analytical procedures
48. ICH Q2B 1996 Validation of analytical procedures: Methodology
49. ICH Q1A (R2) 2003 Stability testing of new drug substances and products
50. ICH Q1B. 1996. Photostability testing of new drug substances and products.
51. ICH Q1C. 1996. Stability testing of new dosage forms.
52. ICH Q1D. 2003. Bracketing and matrixing designs for stability testing of new drug substances and products
53. ICH Q1E. 2004. Evaluation of stability data.
54. ICH Q8 (R2). 1997. Pharmaceutical development.
55. FDA 1997 Guidance for industry: Dissolution testing of immediate release solid oral dosage forms
56. FDA 1998 Guidance for industry: Topical and dermatological drug product NDAs and ANDAs-in vivo bioavailability, bioequivalence, in vitro release, and associate studies
57. FDA 2002 Guidance for industry: Nasal spray and inhalation solution, suspension, and spray drug products-chemistry, manufacturing and controls documentation
58. FDA 2002 Guidance for industry: Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products
59. D Chen, D Cole, and G S Srivatsa 2000 Determination of free and encapsulated oligonucleotides in liposome formulated drug product Journal of Pharmaceutical and Biomedical Analysis 22(5): 791-801.
60. Murugaiah, V, W Zedalis, G Lavine, et al 2010 Reversed-phase high-performance liquid chromatog-raphy method for simultaneous analysis of two liposome-formulated short interfering RNA duplexes Analytical Biochemistry 401(1): 61-67
61. FDA 2002 Guidance for industry: Liposome drug products
62. FDA 2001 Guidance for industry: Bioanalytical method validation